These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 18227745)

  • 21. High Prevalence of Body Dysmorphic Disorder and Moderate to Severe Appearance-Related Obsessive-Compulsive Symptoms Among Rhinoplasty Candidates.
    Ramos TD; de Brito MJA; Suzuki VY; Sabino Neto M; Ferreira LM
    Aesthetic Plast Surg; 2019 Aug; 43(4):1000-1005. PubMed ID: 30607575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Venlafaxine in children and adolescents with attention deficit hyperactivity disorder.
    Mukaddes NM; Abali O
    Psychiatry Clin Neurosci; 2004 Feb; 58(1):92-5. PubMed ID: 14678464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Venlafaxine in the treatment of anxiety disorders.
    Katzman M
    Expert Rev Neurother; 2004 May; 4(3):371-81. PubMed ID: 15853535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder.
    Liebowitz MR; Mangano RM; Bradwejn J; Asnis G;
    J Clin Psychiatry; 2005 Feb; 66(2):238-47. PubMed ID: 15705011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive validity of the overvalued ideas scale: outcome in obsessive-compulsive and body dysmorphic disorders.
    Neziroglu F; Stevens KP; McKay D; Yaryura-Tobias JA
    Behav Res Ther; 2001 Jun; 39(6):745-56. PubMed ID: 11400717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Venlafaxine for treatment of obsessive-compulsive disorder.
    Ananth J; Burgoyne K; Smith M; Swartz R
    Am J Psychiatry; 1995 Dec; 152(12):1832. PubMed ID: 8526258
    [No Abstract]   [Full Text] [Related]  

  • 27. Venlafaxine extended-release treatment of hoarding disorder.
    Saxena S; Sumner J
    Int Clin Psychopharmacol; 2014 Sep; 29(5):266-73. PubMed ID: 24722633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study.
    Zhou J; Wang X; Feng L; Xiao L; Yang R; Zhu X; Shi H; Hu Y; Chen R; Boyce P; Wang G
    BMC Psychiatry; 2021 May; 21(1):260. PubMed ID: 34011310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder.
    Liebowitz MR; Asnis G; Mangano R; Tzanis E
    J Clin Psychiatry; 2009 Apr; 70(4):550-61. PubMed ID: 19358784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.
    Liebowitz MR; Gelenberg AJ; Munjack D
    Arch Gen Psychiatry; 2005 Feb; 62(2):190-8. PubMed ID: 15699296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Venlafaxine in treatment resistant obsessive-compulsive disorder.
    Narayanaswamy JC; Viswanath B; Cherian AV; Math SB; Reddy YC
    J Neuropsychiatry Clin Neurosci; 2014; 26(3):E44-5. PubMed ID: 25093787
    [No Abstract]   [Full Text] [Related]  

  • 32. An open treatment trial of venlafaxine for elderly patients with dysthymic disorder.
    Devanand DP; Juszczak N; Nobler MS; Turret N; Fitzsimons L; Sackeim HA; Roose SP
    J Geriatr Psychiatry Neurol; 2004 Dec; 17(4):219-24. PubMed ID: 15533993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
    Tundo A; Salvati L; Busto G; Di Spigno D; Falcini R
    J Clin Psychiatry; 2007 Oct; 68(10):1552-6. PubMed ID: 17960971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.
    Dell'Osso B; Nestadt G; Allen A; Hollander E
    J Clin Psychiatry; 2006 Apr; 67(4):600-10. PubMed ID: 16669725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A systematic review of the efficacy of venlafaxine for the treatment of fibromyalgia.
    VanderWeide LA; Smith SM; Trinkley KE
    J Clin Pharm Ther; 2015 Feb; 40(1):1-6. PubMed ID: 25294655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
    Bielski RJ; Ventura D; Chang CC
    J Clin Psychiatry; 2004 Sep; 65(9):1190-6. PubMed ID: 15367045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of serotonin norepinephrine reuptake inhibitors in the treatment of attention-deficit hyperactivity disorder in pediatrics.
    Park P; Caballero J; Omidian H
    Ann Pharmacother; 2014 Jan; 48(1):86-92. PubMed ID: 24259607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
    Silverstone PH; Salinas E
    J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of the efficacy and tolerability of reboxetine and sertraline versus venlafaxine in major depressive disorder: a randomized, open-labeled clinical trial.
    Yazicioglu B; Akkaya C; Sarandol A; Akgoz S; Saygin Eker S; Kirli S
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1271-6. PubMed ID: 16820257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Greenhill LL; McNamara NK; Demeter CA; Kotler LA; O'Riordan MA; Myers C; Reed MD
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):433-45. PubMed ID: 17822339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.